Business Standard

Shilpa Medicare

This pharma stock has surged 16% on Friday; zoomed over 100% so far in CY24

Shilpa Medicare hit a multi-year high of Rs 672.50, rallied 16% after the company's CDMO customer reported positive results from pivotal clinical trial & placed binding purchase order.

This pharma stock has surged 16% on Friday; zoomed over 100% so far in CY24
Updated On : 05 Jul 2024 | 11:56 AM IST

Stocks to Watch, May 24: Bayer Crop, Landmark Cars, Shilpa Medicare

Across Asia, markets mirrored the losses seen in Wall Street, with Japan's Nikkei leading the decline with a drop of 1.22 per cent, followed by Korea's Kospi down nearly 1 per cent

Stocks to Watch, May 24: Bayer Crop, Landmark Cars, Shilpa Medicare
Updated On : 24 May 2024 | 8:05 AM IST

Stocks to watch: Mindtree, Vodafone Idea, RIL, IDBI Bank, Shilpa Medicare

Mindtree, Tata Metaliks, Deccan Health Care, Shree Ganesh Remedies and WS Industries are among eight companies that will release quarterly earnings today

Stocks to watch: Mindtree, Vodafone Idea, RIL, IDBI Bank, Shilpa Medicare
Updated On : 13 Jul 2021 | 8:01 AM IST

Shilpa Medicare jumps 26% in 2 days on tie-up with DRL for Covid vaccine

The company has entered into a three-year Definitive Agreement with Dr. Reddy's for production-supply of the Sputnik V vaccine

Shilpa Medicare jumps 26% in 2 days on tie-up with DRL for Covid vaccine
Updated On : 18 May 2021 | 11:00 AM IST

Shilpa Medicare arm inks pact with Dr Reddy's to manufacture Sputnik V vax

Drug firm Shilpa Medicare on Monday said its arm has entered into a definitive agreement with Dr Reddy's Laboratories for manufacturing of Russian COVID-19 vaccine Sputnik V. "The company, via its wholly owned subsidiary Shilpa Biologicals Pvt Ltd (SBPL), has entered into a three year definitive agreement with Dr Reddy's Laboratories for production-supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka," Shilpa Medicare said in a regulatory filing. The targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses (50 million of component 1 and 50 million of component 2), from the date of start of commercial production, the company added. Shilpa Medicare said Dr Reddy's will facilitate the transfer of the sputnik technology to SBPL. Under the agreement, SBPL will be responsible for manufacture of the vaccine, while Dr Reddy's is responsible for distribution/marketing of the vaccine in its ...

Shilpa Medicare arm inks pact with Dr Reddy's to manufacture Sputnik V vax
Updated On : 17 May 2021 | 11:35 AM IST

India's Shilpa Medicare can make 100-200 million doses of Covid-19 shot

The company's shares jumped as much as 9.2% on India's National Stock Exchange following the news

India's Shilpa Medicare can make 100-200 million doses of Covid-19 shot
Updated On : 07 Apr 2021 | 12:30 PM IST

Shilpa Medicare slips 12% on USFDA warning letter for Telangana facility

The company believes that the warning letter will have minimum impact of disruption of supplies and the existing revenues from operations of this facility

Shilpa Medicare slips 12% on USFDA warning letter for Telangana facility
Updated On : 12 Oct 2020 | 9:58 AM IST

Shilpa Medicare slips 5% as USFDA issues Form 483 for Telangana facility

The stock price has more than doubled in the past one month, from the level of Rs 260 on January 24, 2020

Shilpa Medicare slips 5% as USFDA issues Form 483 for Telangana facility
Updated On : 26 Feb 2020 | 12:32 PM IST

Shilpa Medicare hits fresh 52-week high; stock zooms 89% in a month

The company's Ebitda margin expanded by 1,550 basis points to 32.1 per cent in Q3FY20 from 16.6 per cent in Q3FY19

Shilpa Medicare hits fresh 52-week high; stock zooms 89% in a month
Updated On : 24 Feb 2020 | 11:24 AM IST

Shilpa Medicare tanks 36% in 10 days, hits 5-yr low on weak Q1 results

For Q1FY20, the company reported 55 per cent year-on-year (YoY) drop in its consolidated net profit at Rs 15 crore, due to lower sales

Shilpa Medicare tanks 36% in 10 days, hits 5-yr low on weak Q1 results
Updated On : 27 Aug 2019 | 1:59 PM IST

Shilpa Medicare surges 13% after receiving EIR from USFDA

The stock surged 13% to Rs 434 on the BSE in morning trade after the company said it has received EIR from the US health regulator for it's both facilities located at Raichur, Karnataka.

Shilpa Medicare surges 13% after receiving EIR from USFDA
Updated On : 11 Jul 2018 | 10:21 AM IST

Shilpa Medicare gains 7% on EIR for Jadcherla formulations unit

The stock was 7% to Rs 488 on the BSE after the company received EIR from the USFDA for its formulation manufacturing facility in Telangana following the audit in November last year.

Shilpa Medicare gains 7% on EIR for Jadcherla formulations unit
Updated On : 19 Mar 2018 | 10:06 AM IST

Shilpa Medicare slips after USFDA issues 10 observations

The stock slipped 6% to Rs 599 on the BSE in intra-day trade.

Shilpa Medicare slips after USFDA issues 10 observations
Updated On : 06 Dec 2017 | 1:48 PM IST

Shilpa Medicare hits new high; stock up 35% in one month

The stock moved higher to its new high of Rs 746, up 3.5%, extending its 14% rally in past five trading sessions on BSE.

Shilpa Medicare hits new high; stock up 35% in one month
Updated On : 16 Dec 2016 | 1:15 PM IST

Shilpa Medicare hits record high on strong Q2 results

The stock moved higher to its record high of Rs 679, up 9%, extending its Friday's 9% surge on BSE.

Shilpa Medicare hits record high on strong Q2 results
Updated On : 28 Nov 2016 | 10:45 AM IST

Shilpa Medicare surges on USFDA nod for Jadcherla unit

The stock moved higher by 9% to Rs 612 on the BSE.

Shilpa Medicare surges on USFDA nod for Jadcherla unit
Updated On : 26 Jul 2016 | 2:06 PM IST

Shilpa Medicare rallies on getting GMP compliance certificate

The stock rallied 13% to Rs 493 on the BSE in early morning trade.

Shilpa Medicare rallies on getting GMP compliance certificate
Updated On : 13 Apr 2016 | 9:19 AM IST